Literature DB >> 19747631

Delaying DLA-haploidentical hematopoietic cell transplantation after total body irradiation.

Yunchuan Ding1, Marcello Rotta, Scott S Graves, Barry E Storer, Laura J Peterson, George E Sale, Reza Forough, Eustacia Zellmer, George E Georges, Brenda M Sandmaier, Christian S Kuhr, Rainer Storb.   

Abstract

Exposure to accidental or deliberate radiation poses a threat to public health, proving lethal at higher doses in large part because of deleterious effects on marrow. In those cases, allogeneic hematopoietic cell transplantation (HCT) might be required to restore marrow function. Most radiation accident victims will have HLA-haploidentical relatives who could serve as HCT donors. Here, we assessed in a canine HCT model the total body irradiation (TBI) doses after which transplants might be required and successful engraftment would be possible. In an attempt at mimicking the logistical problems likely to exist after radiation accidents, 4-, 8- or 10-day intervals were placed between TBI and HCT. To keep the experimental readout simple, no graft-versus-host disease (GVHD) prevention was administered. All dogs transplanted after a 4-day delay following 700 or 920 cGy TBI successfully engrafted, whereas virtually all those given 450 or 600 cGy rejected their grafts. Transplant delays of 8 and 10 days following 920 cGy TBI also resulted in successful engraftment in most dogs, whereas a delay of 8 days after 700 cGy resulted in virtually uniform graft failure. The time courses of acute GVHD (aGVHD) and rates of granulocyte recovery in engrafting dogs were comparable among dogs regardless of the lengths of delay. In other studies, we showed that most dogs not given HCT survived 700 cGy TBI with intensive supportive care, whereas those given 800 cGy TBI and higher died with marrow aplasia. Thus, DLA-haploidentical HCT was successful even when carried out 4, 8, or 10 days after TBI at or above radiation exposures where dogs survived with intensive care alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747631      PMCID: PMC2757126          DOI: 10.1016/j.bbmt.2009.06.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  33 in total

1.  A delay in bone marrow transplantation after partial conditioning improves engraftment.

Authors:  Hong Xu; Beate G Exner; Paula M Chilton; Michael K Tanner; Yvonne M Mueller; Francine Rezzoug; Suzanne T Ildstad
Journal:  Transplantation       Date:  2004-03-27       Impact factor: 4.939

2.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.

Authors:  R Storb; C Yu; J L Wagner; H J Deeg; R A Nash; H P Kiem; W Leisenring; H Shulman
Journal:  Blood       Date:  1997-04-15       Impact factor: 22.113

3.  Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation.

Authors:  R Storb; R F Raff; T Graham; F R Appelbaum; H J Deeg; F G Schuening; G Sale; K Seidel
Journal:  Biol Blood Marrow Transplant       Date:  1999       Impact factor: 5.742

4.  Abrogation of resistance to and enhancement of DLA-nonidentical unrelated marrow grafts in lethally irradiated dogs by thoracic duct lymphocytes.

Authors:  H J Deeg; R Storb; P L Weiden; H M Shulman; T C Graham; B J Torok-Storb; E D Thomas
Journal:  Blood       Date:  1979-04       Impact factor: 22.113

5.  Resistance to DLA-nonidentical marrow grafts in lethally irradiated dogs.

Authors:  P L Weiden; R Storb; T C Graham; G E Sale; E D Thomas
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

6.  What radiation dose for DLA-identical canine marrow grafts?

Authors:  R Storb; R F Raff; F R Appelbaum; F W Schuening; B M Sandmaier; T C Graham; E D Thomas
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

7.  Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model.

Authors:  Brenda M Sandmaier; Takahiro Fukuda; Theodore Gooley; Cong Yu; Erlinda B Santos; Rainer Storb
Journal:  Exp Hematol       Date:  2003-02       Impact factor: 3.084

8.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.

Authors:  Lauri Burroughs; Marco Mielcarek; Marie-Térèse Little; Gary Bridger; Ron Macfarland; Simon Fricker; Jean Labrecque; Brenda M Sandmaier; Rainer Storb
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

9.  Engraftment of DLA-nonidentical bone marrow facilitated by recipient treatment with anti-class II monoclonal antibody and methotrexate.

Authors:  H J Deeg; G E Sale; R Storb; T C Graham; F Schuening; F R Appelbaum; E D Thomas
Journal:  Transplantation       Date:  1987-09       Impact factor: 4.939

10.  Allogeneic transplant of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors.

Authors:  B M Sandmaier; R Storb; E B Santos; L Krizanac-Bengez; T Lian; P A McSweeney; C Yu; F G Schuening; H J Deeg; T Graham
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

View more
  5 in total

1.  A preclinical model of double- versus single-unit unrelated cord blood transplantation.

Authors:  George E Georges; Vladimir Lesnikov; Szczepan W Baran; Anna Aragon; Marina Lesnikova; Robert Jordan; Ya-Ju Laura Yang; Murad Y Yunusov; Eustacia Zellmer; Shelly Heimfeld; Gopalakrishnan M Venkataraman; Michael A Harkey; Scott S Graves; Rainer Storb; Barry E Storer; Richard A Nash
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-18       Impact factor: 5.742

2.  CD94 Ex Vivo Cultures in a Bone Marrow Transplantation Setting.

Authors:  Kraig Abrams; Scott S Graves; Maura H Parker; Rainer Storb
Journal:  Transplant Direct       Date:  2020-11-16

3.  Inducible costimulator (ICOS) up-regulation on activated T cells in chronic graft-versus-host disease after dog leukocyte antigen-nonidentical hematopoietic cell transplantation: a potential therapeutic target.

Authors:  Masahiko Sato; Rainer Storb; Carol Loretz; Diane Stone; Marco Mielcarek; George E Sale; Andrew R Rezvani; Scott S Graves
Journal:  Transplantation       Date:  2013-07-15       Impact factor: 4.939

4.  Scientific research and product development in the United States to address injuries from a radiation public health emergency.

Authors:  Andrea L DiCarlo
Journal:  J Radiat Res       Date:  2021-09-13       Impact factor: 2.724

Review 5.  Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model.

Authors:  Scott S Graves; Rainer Storb
Journal:  Vet Comp Oncol       Date:  2020-05-26       Impact factor: 2.385

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.